Stoke Therapeutics, Inc. (STOK) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.94: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend.
Stoke Therapeutics is a pre-commercial biopharma developing RNA-targeted therapies using its TANGO platform. Lead candidate zorevunersen (STK-001) is in global Phase 3 EMPEROR study for Dravet syndrome (first patient dosed August 2025, data expected mid-2027); STK-002 for ADOA... Read more
Sell if holding. Engine safety override at $28.94: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on SEC filing concern. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Stoke Therapeutics, Inc.
Latest news
- NEWS BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target — benzinga May 11, 2026 positive
- NEWS Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate. — benzinga May 7, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezorevunersen (STK-001)10-K Item 1A: 'We have invested substantially all of our efforts and financial resources in the development of TANGO and our current lead product candidate, zorevunersen'
Material Events(8-K, last 90d)
- 2026-04-07Item 5.02LOWG. Clare Kahn, Ph.D. appointed to Board as Class I director effective April 3, 2026. Appointed to Nominating and Corporate Governance Committee and as chairperson of R&D Committee.SEC filing →
- 2026-03-27Item 4.01HIGHAudit Committee dismissed KPMG LLP as independent auditor on March 23, 2026. KPMG's reports for FY2025 and FY2024 were unqualified with no reportable events or disagreements. New auditor to be named.SEC filing →
- 2026-03-03Item 5.02LOWBoard approved $697,125 discretionary bonus for CEO Ian F. Smith for 2025 performance (150% of target). Represents his full target annual bonus amount.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.94: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $27.31. Score 5.0/10, moderate confidence.
Take-profit target: $39.24 (+33.6% upside). Prior stop was $27.31. Stop-loss: $27.31.
Concentration risk — Pipeline: zorevunersen (STK-001); Quality below floor (2.8 < 4.0).
Stoke Therapeutics, Inc. trades at a P/E of N/A (forward -9.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover STOK with a consensus score of 4.4/5. Average price target: $45.
What does Stoke Therapeutics, Inc. do?Stoke Therapeutics is a pre-commercial biopharma developing RNA-targeted therapies using its TANGO platform. Lead...
Stoke Therapeutics is a pre-commercial biopharma developing RNA-targeted therapies using its TANGO platform. Lead candidate zorevunersen (STK-001) is in global Phase 3 EMPEROR study for Dravet syndrome (first patient dosed August 2025, data expected mid-2027); STK-002 for ADOA is in Phase 1.